Sagimet (SGMT) Director George Kemble Sells 20,206 Shares

What Happened

• George Kemble, a director of Sagimet Biosciences (SGMT), exercised vested options to acquire a total of 20,206 shares (9,751 + 10,455) at $6.36 per share (total exercise cost $128,510) on 2026-08-11, and sold those 20,206 shares in the open market the same day for total gross proceeds of $201,147. The filing reports a net pre-tax difference of roughly $72,637 between sale proceeds and exercise cost.
• The transactions include the option exercise entries (reported as derivative conversions) and the subsequent sale of the acquired shares.

Key Details

• Transaction date: 2026-08-11; Form 4 filed 2026-08-12 (appears timely).
• Exercise/cost: 20,206 shares acquired at $6.36 per share = $128,510.
• Sale: 20,206 shares sold at a weighted average price of $9.95 (range $9.95–$9.99) = $201,147. The filer offered to provide per-price breakdown on request.
• Footnotes: Transactions effected under a Rule 10b5-1 trading plan adopted Aug 21, 2025 (F1). The options exercised were fully vested as of the date (F3).
• Shares owned after the transactions: Not disclosed in the filing.

Context

• This was an option exercise followed by an immediate open-market sale under a pre-established 10b5-1 plan. The derivative "disposed" lines at $0 reflect the conversion/exercise of the options (the options ceased to exist after exercise).
• Such exercises + sales are common for executives and directors to monetize vested equity; the 10b5-1 plan indicates trades were pre-specified and not ad hoc.